Oct 2 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to ...

Picasso's extraordinary capacity to work in a variety of mediums and styles has amazed his critics since the first years of the century. This collection of critical and personal reactions to Picasso ...

Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, part of a broader push to shore up the company’s supply chain.

YouTuber Lilly Singh has come out as bisexual in a tweet that celebrates her sexuality, race and gender. She tweeted: "Female, coloured, bisexual" to her 5.74 million Twitter followers and ...

Eli Lilly Says Ebglyss Improves Atopic Dermatitis Symptoms in New Phase 3B Data New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS improved skin (including hand and face) and itch among ...

Earnings Report 1.453 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.438 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.271 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs. The Lilly Medicine Foundry, located in Lebanon, Indiana, is a first-of-its ...

Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other ...

Oct 2 (Reuters) - The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to ...